Patent application number | Description | Published |
20090325990 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS - Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. | 12-31-2009 |
20100184758 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 07-22-2010 |
20100234409 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity - Compounds of the formulae (I) and (II): (wherein Q, X, E, G | 09-16-2010 |
20110201615 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS - Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 08-18-2011 |
20120264777 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 10-18-2012 |
20150322056 | Factor IXa Inhibitors - The present invention provides a compound of Formula (I) | 11-12-2015 |
20150329562 | Factor IXa Inhibitors - The present invention provides a compound of Formula (I) | 11-19-2015 |
20150368269 | Factor IXa Inhibitors - The present invention provides a compound of Formula (I) | 12-24-2015 |